Clinical trial
Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential…
NCT00425373 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00425373 |
|---|---|
| Title | Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension |
| Official title | A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled, Factorial Study to Evaluate the Efficacy and Safety of 8-week Treatment With Valsartan (40 and 80 mg) and Amlodipine (2.5 and 5 mg) Combined and Alone in Essential Hypertensive Patients |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Essential Hypertension |
| Intervention type | Drug |
| Interventions | Valsartan + amlodipine 40/2.5 mg, Valsartan + amlodipine 40/5 mg, Valsartan + amlodipine 80/2.5 mg, Valsartan + amlodipine 80/5 mg, Valsartan 40 mg, Valsartan 80 mg, Amlodipine 2.5 mg, Amlodipine 5 mg, Placebo |
| Enrollment | 1,474 |
| Start date | Nov 1, 2006 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Jan 23, 2007 |
| Last update posted | Apr 29, 2011 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: